可持续减脂。保留肌肉。更健康的身体。

大多数尝试减重的人都经历过多次。减重难以持久的原因并非道德缺失，而是生物学在捍卫其先前的体重。食欲激素（饥饿素、瘦素、GLP-1）会发生变化以增加摄入量；静息代谢率会向下调整；几个月后，系统会将身体拉回其先前的设定点。

什么能改变结果：

• 正确的诊断 - 识别潜在驱动因素（胰岛素抵抗、低睾酮、甲状腺功能减退、睡眠呼吸暂停、药物副作用）
• 充足的蛋白质和阻力训练 - 保留瘦肌肉，确保减掉的是脂肪而非肌肉
• 可持续的结构 - 一个你真正能坚持的框架，而不是6周的冲刺
• 适时的药物治疗 - 现代GLP-1药物能显著改变符合条件患者的食欲生物学
• 长期坚持 - 维持比减重更难；结构化方案有所帮助

如果没有这些要素，即使是自律的努力也往往会导致 5-10% 的减重，随后在 1-2 年内反弹。有了这些要素，实现 10-20% 的持续减重是现实的——达到这一幅度后，心脏代谢风险、脂肪肝、睡眠呼吸暂停、睾酮水平和勃起功能都会发生显著改善。

体重也通过共享的代谢生物学与其他器官系统相连——这就是为什么综合护理与 糖尿病护理, 心脏筛查, 睾酮缺乏， 和 勃起功能障碍 比单纯的减重能产生更好的效果。

• “我只是需要更自律。” 有时是真的；但往往不是。未治疗的甲状腺功能减退、低睾酮、睡眠呼吸暂停或胰岛素抵抗会使减重变得异常困难。诊断出这些问题是最高效的举措。
• “GLP-1 是作弊。” 它们是用于治疗疾病的处方药。同样的逻辑也可以称胰岛素对于糖尿病患者是“作弊”。它们是一种工具——而不是捷径，且并不适合所有人。
• "I'll just take semaglutide for 3 months and be done." 在没有持续生活方式改变的情况下停止GLP-1药物治疗通常会导致体重反弹。对于致力于持续行为改变的特定患者而言，这些是长期工具。
• “少吃碳水/米饭/糖就能解决一切问题。” 单一食物的规避很少能解决潜在的胰岛素抵抗。整体饮食模式、总能量平衡、睡眠和身体活动比任何单一食物都更重要。
• “有氧运动是减肥的关键。” 有氧运动很重要，但阻力训练才是减肥期间保持瘦肌肉的关键，这使减肥成果更具可持续性且代谢更健康。跳过阻力训练是一个常见的错误。
• “我的体重没有影响我的健康——我感觉很好。” 许多与体重相关的疾病（糖尿病前期、脂肪肝、高血压、低睾酮、阻塞性睡眠呼吸暂停）在晚期之前是无症状的。感觉良好令人欣慰，但不能作为诊断依据。

在您访问之前。 您的个人健康礼宾部会分享一份简短的摄入表，涵盖当前体重、既往尝试、病史、药物、症状和目标。如果需要验血，预约前会提供禁食说明（10-12小时，允许喝水）。

在您访问期间。 咨询时长为45-60分钟。医生将重点了解您的体重和代谢史，测量体重、身高、BMI、腰围和血压。现场进行抽血检查，包括空腹血糖、糖化血红蛋白(HbA1c)、全套血脂、肝功能、肾功能、甲状腺功能，并在必要时检测睾酮水平。同时进行睡眠呼吸暂停风险筛查。

检查结果。 实验室检查结果将在2个工作日内出具。我们将安排专门的结果解读咨询，用通俗易懂的语言详细说明每一项检查结果——分析导致您体重问题的因素、对您而言最高效的干预措施，以及预期的现实效果。治疗方案将从预期获益、实际时间表、副作用情况和费用等方面进行说明。当天无需做出任何决定，没有任何压力。

您访问后。 我们将提供一份清晰的书面计划，涵盖生活方式调整重点、已启动或考虑使用的药物、监测时间表以及下次复诊日期。常规复诊频率为1个月和3个月，之后持续进行——如果开始使用GLP-1药物，早期几周将进行更密切的剂量调整。对于无需体格检查的常规随访，我们提供远程咨询服务。

保密。 记录已加密。未经您明确同意，Hisential 不会与雇主、家庭或保险公司共享信息，法规或法律要求的情况除外。

GLP-1 is a gut hormone released after eating. Medicines that act on this pathway improve glucose-dependent insulin release, slow stomach emptying and affect appetite centres in the brain. Many patients describe earlier fullness and less persistent thinking about food, rather than a stimulant-like loss of appetite.

Medication reduces the biological pressure that makes a sustained energy deficit difficult. It does not replace adequate protein, resistance training, sleep or a practical eating plan. Those remain essential for preserving muscle and maintaining the result.

For a focused explanation of eligibility, screening, research outcomes and muscle preservation, see our guide to GLP-1 weight loss treatment.

Under local clinical guidance, GLP-1 treatment may be considered at BMI 27.5 and above without a related medical condition, or BMI 25 and above with a chronic condition such as diabetes or fatty liver disease. Because metabolic risk can rise at a lower BMI in Asian patients, the decision also takes account of waist circumference and metabolic markers.

Before any prescription is issued, assessment includes weight, waist circumference, blood pressure, HbA1c or fasting glucose, lipids, liver and kidney function, thyroid function and testosterone where relevant. The doctor also checks pregnancy plans, pancreatitis risk, relevant cancer history, eating disorders, current medicines, sleep, alcohol, training history and previous weight loss attempts.

Doses increase slowly to improve tolerability. Nausea, reflux, constipation and occasional vomiting or diarrhoea are most common after an increase and often settle with smaller meals, lower-fat food, good hydration and stopping at the first sense of fullness. Severe persistent abdominal pain or inability to keep fluids down needs prompt medical review.

Gallstones and pancreatitis are less common but important risks. Lean tissue loss is also a central concern, so protein, resistance training and strength or body-composition tracking form part of treatment. Weight, waist, blood pressure and key blood markers are recorded at baseline and reviewed at three and six months, with shorter reviews during dose escalation.

Appetite commonly returns after treatment stops and weight regain is common without a maintenance plan. The stopping or maintenance strategy is therefore discussed before treatment, rather than after progress has been made.

Subcutaneous fat sits under the skin. Visceral fat surrounds abdominal organs and is more strongly associated with insulin resistance, fatty liver, high triglycerides, hypertension and type 2 diabetes. A person can have a BMI in the conventional normal range but still carry substantial visceral fat.

For Asian men, a waist circumference of 90 cm or more signals central obesity. Measure at navel level after a normal exhale, without compressing the skin. Metabolic syndrome is usually identified when at least three markers cluster: central obesity, blood pressure of 130/85 mmHg or above, triglycerides of 1.7 mmol/L or above, HDL below 1.0 mmol/L, or fasting glucose of 5.6 mmol/L or above. Insulin resistance is the common upstream driver for many of these changes.

Progress is therefore tracked through weight, waist, blood pressure, metabolic blood markers and physical function. This shows whether visceral fat is falling while muscle is being preserved, even when scale weight changes slowly.

Excess visceral fat contributes to hypertension, abnormal lipids and type 2 diabetes, as well as obstructive sleep apnoea and fatty liver disease. It can also affect sexual and hormonal health through blood-vessel dysfunction, lower testosterone and poorer sleep. Long-term excess body fat is associated with increased risk of several cancers, including colon, oesophageal, pancreatic, kidney and liver cancers.

The first target does not need to be an ideal body weight. A sustained loss of five to ten percent is often enough to improve blood pressure, HbA1c, triglycerides, liver markers and sleep apnoea severity. That makes measurable health change a more useful target than appearance alone.